Synergy Pharmaceuticals begins Phase IIb trial of Plescanatide in IBS-C Synergy Pharmaceuticals (SGYP) announced that dosing has commenced in a Phase IIb clinical trial of plecanatide to treat patients with constipation-predominant irritable bowel syndrome, or IBS-C. This trial is being conducted at 70 sites in the U.S. and includes 350 patients with IBS-C who will be treated with one of four doses of plecanatide or placebo, taken once daily over a period of 12 weeks. PAREXEL International (PRXL) is the Contract Research Organization for the trial.
PAREXEL revenue guidance looks 'aggressive,' says Jefferies Jefferies views PAREXEL's 2015 revenue guidance as "aggressive" saying the company's backlog conversion must accelerate faster than 2014 levels just to hit the low end of the outlook. The firm keeps a Hold rating on the stock with a $57 price target.